ovarian cancer clinical trials results

niraparib versus placebo
ENGOT-OV16/NOVA non-gBRCA,
NCT01847274
niraparib (300 mg) once daily
versus
placebo
patients with platinum-sensitive, recurrent ovarian cancerdouble-blind
ENGOT-OV16/NOVA gBRCA, 2017
NCT01847274
niraparib (300 mg) once daily as maintenance treatment
versus
placebo
patients with platinum-sensitive, recurrent ovarian cancer with germline BRCA mutation double-blind
olaparib versus placebo
SOLO2/ENGOT-Ov21 ,
NCT01874353
olaparib 300 mg in two 150 mg tablets, twice daily
versus
placebo
patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutationdouble-blind
international
olaparid versus placebo
Ledermann, 2012
NCT00753545
olaparib, at a dose of 400 mg twice daily
versus
placebo
patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer with or without BRCA1 or BRCA2 germline mutations, who had received two or more platinum-based regimens and had had a partial or complete response to their most recent platinum-based regimendouble-blind